← Human Trials & Peer-Reviewed Studies
[Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis]
Plain-language guide to PMID 21311486 (2010): controlled clinical trial study of Glatiramer Acetate in 158 patients, multiple sclerosis.
Key Facts
- PMID
- 21311486
- Journal
- Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
- Year
- 2010
- Study type
- Controlled Clinical Trial
- Authors
- Petrova LV et al. (4 authors)
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glatiramer Acetate in the context of multiple sclerosis in this controlled clinical trial publication.
Demographic data, severity of MS patient's state, ultra-sound and hormonal data assessing the thyroid gland function were analyzed.
Who Took Part
The study group was 158 patients.
PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, both men and women.
What Was Measured
Demographic data, severity of MS patient's state, ultra-sound and hormonal data assessing the thyroid gland function were analyzed.
PubMed files the paper under topics including Glatiramer Acetate, Immunosuppressive Agents, Multiple Sclerosis, Peptides and Thyroid Gland.
What This Means in Plain Language
This is a controlled clinical trial of Glatiramer Acetate in 158 patients in people with multiple sclerosis.
The publication is from 2010 (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova), a journal based in Russia (Federation).
More context: the Glatiramer Acetate compound page, Multiple sclerosis research.
Our Notes on the Compound
Glatiramer Acetate: A mix of synthetic amino-acid chains (Copaxone) used in relapsing multiple sclerosis.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.